Analysa A
Research Subjects
Analysa A has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Desak Putu Oki Lestari
Department of Anatomical Pathology, Faculty of Medicine and Health Sciences, Warmadewa University, Bali, Indonesia
1 shared publication - I Nyoman Putu Riasa
Division of Plastic Reconstructive and Aesthetic Surgery and Burn Unit, Department of Surgery, Udayana University, Ngoerah Hospital, Bali
1 shared publication - Ni Putu Diah Witari
Department of Histology, Faculty of Medicine and Health Sciences, Universitas Warmadewa, Bali, Indonesia
1 shared publication - Ni Wayan Armerinayanti
Department of Pathology, Faculty of Medicine and Health Sciences, Warmadewa University, Indonesia
1 shared publication - Putu Indah Budi Apsari
Faculty of Medicine and Health sciences Warmadewa University
1 shared publication
Latest Publications
- Open Access
- 30 December 2025
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 4 (18) , 3008
Prognostic Role of Programmed Death Ligand-1 and P16 in Advanced Penile Cancer
Persistent infection of high risk human papilloma virus (HPV) is a recognized driver oncogenesis in penile cancer, often characterized by upregulation of p16 and immune evasion via programmed death-ligand 1 (PD-L1) expression. This study aimed to assess the prognostic significance of p16 and PD-L1 in advanced penile cancer. Methods: A total of 80 cases of advanced penile cancer were retrospectively evaluated. Expression of p16 and PD-L1 was assessed by immunohistochemistry. Various clinicopathological parameters, such as patient age, tumor dimensions, histopathological grading, evidence of vascular invasion, and presence of lymphatic metastasis, were systematically evaluated in relation to PD-L1 overexpression. PD-L1 overexpression was observed in 37 (46.25%) of cases. PD-L1 positivity was significantly higher in p16 positive tumors (57.5%) than in p16 negative cases (35%) (p=0.044). Elevated PD-L1 expression strongly correlated with increased tumor dimension (p=0.002), advanced histological grade (p=0.000), the presence of vascular invasion (p=0.001), and lymphatic node involvement (p=0.000). PD-L1 overexpression was not significantly associated with the age of patients (p=0.932). PD-L1 and p16 are associated with clinicopathological features in advanced penile squamous cell carcinoma and may serve as prognostic biomarkers. Further multi-institutional studies are needed to clarify their predictive value for tailoring immunotherapy in penile cancer.
- 30 December 2025
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 4 (18) , 3008
Open AccessPrognostic Role of Programmed Death Ligand-1 and P16 in Advanced Penile Cancer
Persistent infection of high risk human papilloma virus (HPV) is a recognized driver oncogenesis in penile cancer, often characterized by upregulation of p16 and immune evasion via programmed death-ligand 1 (PD-L1) expression. This study aimed to assess the prognostic significance of p16 and PD-L1 in advanced penile cancer. Methods: A total of 80 cases of advanced penile cancer were retrospectively evaluated. Expression of p16 and PD-L1 was assessed by immunohistochemistry. Various clinicopathological parameters, such as patient age, tumor dimensions, histopathological grading, evidence of vascular invasion, and presence of lymphatic metastasis, were systematically evaluated in relation to PD-L1 overexpression. PD-L1 overexpression was observed in 37 (46.25%) of cases. PD-L1 positivity was significantly higher in p16 positive tumors (57.5%) than in p16 negative cases (35%) (p=0.044). Elevated PD-L1 expression strongly correlated with increased tumor dimension (p=0.002), advanced histological grade (p=0.000), the presence of vascular invasion (p=0.001), and lymphatic node involvement (p=0.000). PD-L1 overexpression was not significantly associated with the age of patients (p=0.932). PD-L1 and p16 are associated with clinicopathological features in advanced penile squamous cell carcinoma and may serve as prognostic biomarkers. Further multi-institutional studies are needed to clarify their predictive value for tailoring immunotherapy in penile cancer.